Omega Therapeutics' epigenomic medicines reduce MYC expression by 55% in early study of cancer patients - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Omega Therapeutics, a company designing genetic medicines that dial the output of genes up or down, on Tuesday morning revealed the first data from a clinical trial of its so-called epigenomic controllers. The treatment represses the notorious MYC gene, which…